Literature DB >> 25464904

MicroRNAs as therapeutic targets in atherosclerosis.

Xavier Loyer1, Ziad Mallat, Chantal M Boulanger, Alain Tedgui.   

Abstract

INTRODUCTION: Atherosclerosis is a chronic inflammatory disease of the arterial wall. A number of phenotypic cell changes occur during the development and progression of atherosclerosis. MicroRNAs (miRNAs) are key regulators of gene expression that act at the post-transcriptional level. They have been implicated in cardiovascular diseases, including atherosclerosis. AREAS COVERED: This review provides an overview of our knowledge about the expression and the roles of miRNAs in different cell types involved in atherosclerosis, with a focus on experimental strategies to modulate miRNA expression and their therapeutic effects in animal models of atherosclerosis. miRNA expression is regulated by inflammatory conditions and by shear stress in endothelial cells. Therapeutic approaches using antagomiR and miRNA mimic delivery and have been shown potentially effective in atherosclerosis. Moreover, a large body of evidence exists supporting a role for not only intracellular miRNA, but also miRNA carried by extracellular vesicles that are involved in inter-cellular communication through the transfer of miRNA. EXPERT OPINION: Modulation of miRNA expression could represent novel innovative therapeutic approaches to treat atherosclerosis by targeting a single cell type or specific pathways. Future challenges will consist in deciphering the mechanisms involved in miRNA regulation and in improving cell-specific delivery of 'miR-drugs' by alternative strategies, including miRNA-enriched micro vesicles.

Entities:  

Keywords:  atherosclerosis; endothelium; inflammation; microRNAs; therapy

Mesh:

Substances:

Year:  2014        PMID: 25464904     DOI: 10.1517/14728222.2014.989835

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

Review 1.  CircRNA-miRNA interactions in atherogenesis.

Authors:  Kind-Leng Tong; Ke-En Tan; Yat-Yuen Lim; Xin-Yi Tien; Pooi-Fong Wong
Journal:  Mol Cell Biochem       Date:  2022-05-23       Impact factor: 3.396

2.  Mechanosensitive pathways are regulated by mechanosensitive miRNA clusters in endothelial cells.

Authors:  Sean Herault; Jarka Naser; Daniele Carassiti; K Yean Chooi; Rosa Nikolopoulou; Marti Llopart Font; Miten Patel; Ryan Pedrigi; Rob Krams
Journal:  Biophys Rev       Date:  2021-10-23

3.  Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.

Authors:  Jan Novák; Veronika Olejníčková; Nikola Tkáčová; Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

4.  MicroRNA-7 Deficiency Ameliorates the Pathologies of Acute Lung Injury through Elevating KLF4.

Authors:  Juanjuan Zhao; Chao Chen; Mengmeng Guo; Yijin Tao; PanPan Cui; Ya Zhou; Nalin Qin; Jing Zheng; Jidong Zhang; Lin Xu
Journal:  Front Immunol       Date:  2016-10-07       Impact factor: 7.561

5.  MicroRNA‑126 inhibits endothelial permeability and apoptosis in apolipoprotein E‑knockout mice fed a high‑fat diet.

Authors:  Xiao-Wen Cheng; Yu-Feng Wan; Qing Zhou; Yuan Wang; Hua-Qing Zhu
Journal:  Mol Med Rep       Date:  2017-07-12       Impact factor: 2.952

Review 6.  RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.

Authors:  Christoph S Nabzdyk; Leena Pradhan-Nabzdyk; Frank W LoGerfo
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

7.  Differentially Tolerized Mouse Antigen Presenting Cells Share a Common miRNA Signature Including Enhanced mmu-miR-223-3p Expression Which Is Sufficient to Imprint a Protolerogenic State.

Authors:  Matthias Bros; Mahmoud Youns; Verena Kollek; Diana Buchmüller; Franziska Bollmann; Ean-Jeong Seo; Jonathan Schupp; Evelyn Montermann; Svetlana Usanova; Hartmut Kleinert; Thomas Efferth; Angelika B Reske-Kunz
Journal:  Front Pharmacol       Date:  2018-08-17       Impact factor: 5.810

Review 8.  Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs.

Authors:  Daria Skuratovskaia; Maria Vulf; Aleksandra Komar; Elena Kirienkova; Larisa Litvinova
Journal:  Biomolecules       Date:  2019-06-11

Review 9.  Unveiling ncRNA regulatory axes in atherosclerosis progression.

Authors:  Estanislao Navarro; Adrian Mallén; Josep M Cruzado; Joan Torras; Miguel Hueso
Journal:  Clin Transl Med       Date:  2020-02-03

Review 10.  Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates.

Authors:  Santiago Grijalvo; Adele Alagia; Andreia F Jorge; Ramon Eritja
Journal:  Genes (Basel)       Date:  2018-02-06       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.